VRNA vs. TEVA, SMMT, GMAB, ITCI, VTRS, MRNA, RDY, PCVX, SRPT, and QGEN
Should you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
Verona Pharma vs.
Teva Pharmaceutical Industries (NYSE:TEVA) and Verona Pharma (NASDAQ:VRNA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.
54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 85.9% of Verona Pharma shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 4.8% of Verona Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Teva Pharmaceutical Industries had 11 more articles in the media than Verona Pharma. MarketBeat recorded 19 mentions for Teva Pharmaceutical Industries and 8 mentions for Verona Pharma. Teva Pharmaceutical Industries' average media sentiment score of 0.88 beat Verona Pharma's score of 0.88 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.
Verona Pharma has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Verona Pharma's return on equity.
Verona Pharma has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Verona Pharma is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Teva Pharmaceutical Industries has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.
Teva Pharmaceutical Industries received 1002 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 80.84% of users gave Verona Pharma an outperform vote while only 67.87% of users gave Teva Pharmaceutical Industries an outperform vote.
Teva Pharmaceutical Industries presently has a consensus target price of $23.57, indicating a potential upside of 38.53%. Verona Pharma has a consensus target price of $57.14, indicating a potential downside of 10.98%. Given Teva Pharmaceutical Industries' higher probable upside, equities research analysts clearly believe Teva Pharmaceutical Industries is more favorable than Verona Pharma.
Summary
Teva Pharmaceutical Industries and Verona Pharma tied by winning 9 of the 18 factors compared between the two stocks.
Get Verona Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verona Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:VRNA) was last updated on 2/21/2025 by MarketBeat.com Staff
